{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:09:04Z","timestamp":1789056544506,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.rmed.2026.109060","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:42:17Z","timestamp":1785253337000},"page":"109060","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Weight gain is associated with reduced inflammation in children with cystic fibrosis on elexacaftor\/tezacaftor\/ivacaftor"],"prefix":"10.1016","volume":"262","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5626-5310","authenticated-orcid":false,"given":"Naz","family":"G\u00f6kbulut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3491-6363","authenticated-orcid":false,"given":"Pascal","family":"Heer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ezri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Mornand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6849-6469","authenticated-orcid":false,"given":"Nicolas","family":"Regamey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Rochat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2898-3710","authenticated-orcid":false,"given":"Alexis","family":"Rybak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0284-9705","authenticated-orcid":false,"given":"Sylvain","family":"Blanchon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.rmed.2026.109060_bib1","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/ppul.20913","article-title":"Assessment of body composition in pediatric patients with cystic fibrosis","volume":"43","author":"Wells","year":"2008","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.rmed.2026.109060_bib2","article-title":"Weight increase in people with cystic fibrosis on CFTR modulator therapy is mainly due to increase in fat mass","volume":"14","author":"Mouzaki","year":"2023","journal-title":"Front Pharmacol. Frontiers"},{"key":"10.1016\/j.rmed.2026.109060_bib3","first-page":"393","article-title":"Growth failure in children with cystic fibrosis","volume":"25","author":"Scaparrotta","year":"2012"},{"key":"10.1016\/j.rmed.2026.109060_bib4","article-title":"Trends in growth and maturation in children with cystic fibrosis throughout nine decades","volume":"13","author":"Mason","year":"2022","journal-title":"Front Endocrinol. Frontiers"},{"key":"10.1016\/j.rmed.2026.109060_bib5","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.29359","article-title":"Newly discovered cutting-edge triple combination cystic fibrosis therapy: a systematic review","author":"Dawood","year":"2022","journal-title":"Cureus Journal"},{"issue":"5","key":"10.1016\/j.rmed.2026.109060_bib6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med. American Thoracic Society - AJRCCM"},{"issue":"2","key":"10.1016\/j.rmed.2026.109060_bib7","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jcf.2022.10.003","article-title":"Elexacaftor\/Tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: report of promise-GI","volume":"22","author":"Schwarzenberg","year":"2023","journal-title":"Journal of Cystic Fibrosis. Elsevier"},{"issue":"6","key":"10.1016\/j.rmed.2026.109060_bib8","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.jcf.2023.06.010","article-title":"Body mass index and nutritional intake following elexacaftor\/tezacaftor\/ivacaftor modulator therapy in adults with cystic fibrosis","volume":"22","author":"Caley","year":"2023","journal-title":"J. Cyst. Fibros."},{"issue":"6","key":"10.1016\/j.rmed.2026.109060_bib10","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/ppul.23149","article-title":"Quality of life in children with CF: psychometrics and relations with stress and mealtime behaviors","volume":"50","author":"Driscoll","year":"2015","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.rmed.2026.109060_bib11","unstructured":"Zolin A, Adamoli A, Bakkeheim E. ECFSPR Annual Report 2023. Karup (Denmark): European Cystic Fibrosis Society Patient Registry (ECFSPR); 2025."},{"issue":"6","key":"10.1016\/j.rmed.2026.109060_bib12","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/ppul.26388","article-title":"The impact of elexacaftor\/tezacaftor\/ivacaftor on body composition in a small cohort of youth with cystic fibrosis","volume":"58","author":"Granados","year":"2023","journal-title":"Pediatr. Pulmonol."},{"issue":"12","key":"10.1016\/j.rmed.2026.109060_bib13","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med. American Thoracic Society - AJRCCM"},{"issue":"12","key":"10.1016\/j.rmed.2026.109060_bib14","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1002\/ppul.27272","article-title":"Effects on growth, weight and body composition after CFTR modulators in children with cystic fibrosis","volume":"59","author":"L\u00f3pez C\u00e1rdenes","year":"2024","journal-title":"Pediatr. Pulmonol."},{"issue":"11","key":"10.1016\/j.rmed.2026.109060_bib15","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1002\/ppul.27125","article-title":"Effectiveness and safety of elexacaftor\/tezacaftor\/ivacaftor treatment in children aged 6-11 years with cystic fibrosis in a real-world setting","volume":"59","author":"Dacc\u00f2","year":"2024","journal-title":"Pediatr. Pulmonol."},{"issue":"1","key":"10.1016\/j.rmed.2026.109060_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.27463","article-title":"Growth, body composition, and strength of children with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor (ETI)","volume":"60","author":"Boat","year":"2025","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.rmed.2026.109060_bib17","first-page":"132","article-title":"Body mass, linear growth, and body composition before and after the introduction of elexacaftor\/tezacaftor\/ivacaftor among children and adults with cystic fibrosis","volume":"54","author":"Bader-Larsen","year":"2025"},{"issue":"12","key":"10.1016\/j.rmed.2026.109060_bib18","first-page":"1898","article-title":"Inflammation and infection in cystic fibrosis: update for the clinician","volume":"9","author":"Petrocheilou","year":"2022","journal-title":"Children (Basel)"},{"issue":"1","key":"10.1016\/j.rmed.2026.109060_bib19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00408-025-00806-6","article-title":"The role of triple CFTR modulator therapy in reducing systemic inflammation in cystic fibrosis","volume":"203","author":"Garc\u00eda","year":"2025","journal-title":"Lung"},{"issue":"5","key":"10.1016\/j.rmed.2026.109060_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e15756","article-title":"Elexacaftor - Tezacaftor - Ivacaftor treatment improves systemic infection parameters and Pseudomonas aeruginosa colonization rate in patients with cystic fibrosis a monocentric observational study","volume":"9","author":"Schnell","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.rmed.2026.109060_bib21","doi-asserted-by":"crossref","DOI":"10.1177\/17534666251314706","article-title":"Elexacaftor\/Tezacaftor\/ivacaftor and inflammation in children and adolescents with cystic fibrosis: a retrospective dual-center cohort study","volume":"19","author":"Pepe","year":"2025","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.rmed.2026.109060_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.medmic.2022.100057","article-title":"Intestinal dysbiosis and inflammation in cystic fibrosis impacts gut and multi-organ axes","volume":"13","author":"Wrigley-Carr","year":"2022","journal-title":"Medicine in Microecology."},{"issue":"5","key":"10.1016\/j.rmed.2026.109060_bib23","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jcf.2017.03.010","article-title":"Age-dependent variation of fecal calprotectin in cystic fibrosis and healthy children","volume":"16","author":"Garg","year":"2017","journal-title":"Journal of Cystic Fibrosis. Elsevier"},{"issue":"4","key":"10.1016\/j.rmed.2026.109060_bib24","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/MPG.0000000000001544","article-title":"Fecal calprotectin in cystic fibrosis and its relation to disease parameters","volume":"65","author":"Ellemunter","year":"2017","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"3","key":"10.1016\/j.rmed.2026.109060_bib25","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jcf.2023.10.001","article-title":"Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and calprotectin over one year of treatment with elexacaftor-tezacaftor-ivacaftor in people with CF aged \u226512 years \u2013 the RECOVER study","volume":"23","author":"Mainz","year":"2024","journal-title":"Journal of Cystic Fibrosis. Elsevier"},{"key":"10.1016\/j.rmed.2026.109060_bib26","first-page":"76","article-title":"Dietary intake remains unchanged while nutritional status improves in children and adults with cystic fibrosis on elexacaftor\/tezacaftor\/ivacaftor","volume":"50","author":"Enaud","year":"2025"},{"key":"10.1016\/j.rmed.2026.109060_bib27","article-title":"Body composition in individuals with cystic fibrosis","volume":"26","author":"Soltman","year":"2021","journal-title":"J. Clin. Transl. Endocrinol."},{"issue":"4","key":"10.1016\/j.rmed.2026.109060_bib28","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1164\/ajrccm.158.4.9710079","article-title":"Inspiratory muscle function and body composition in cystic fibrosis","volume":"158","author":"Ionescu","year":"1998","journal-title":"Am J Respir Crit Care Med. American Thoracic Society - AJRCCM"},{"issue":"3","key":"10.1016\/j.rmed.2026.109060_bib29","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1164\/ajrccm.162.3.9910118","article-title":"Bone density, body composition, and inflammatory status in cystic fibrosis","volume":"162","author":"Ionescu","year":"2000","journal-title":"Am J Respir Crit Care Med. American Thoracic Society - AJRCCM"},{"issue":"1","key":"10.1016\/j.rmed.2026.109060_bib30","first-page":"1","article-title":"Fecal calprotectin and phenotype severity in patients with cystic fibrosis: a systematic review and meta-analysis. Pediatric gastroenterology","volume":"25","author":"Talebi","year":"2022","journal-title":"Hepatology & Nutrition"},{"key":"10.1016\/j.rmed.2026.109060_bib31","first-page":"560","article-title":"The impact of modulator therapies on pancreatic exocrine function: the good, the bad and the potentially ugly","volume":"21","author":"Freeman","year":"2022"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126004282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126004282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:41:01Z","timestamp":1789054861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611126004282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":30,"alternative-id":["S0954611126004282"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2026.109060","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Weight gain is associated with reduced inflammation in children with cystic fibrosis on elexacaftor\/tezacaftor\/ivacaftor","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2026.109060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109060"}}